{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:08:46Z","timestamp":1793304526272,"version":"4.5.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100017268","name":"Berlin Institute of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017268","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.jbspin.2022.105406","type":"journal-article","created":{"date-parts":[[2022,5,7]],"date-time":"2022-05-07T11:14:13Z","timestamp":1651922053000},"page":"105406","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Current and future treatment in primary Sj\u00f6gren's syndrome\u00a0\u2013\u00a0A still challenging development"],"prefix":"10.1016","volume":"89","author":[{"given":"Jacob","family":"Ritter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yidan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana-Luisa","family":"Stefanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"D\u00f6rner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2022.105406_bib0365","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMcp1702514","article-title":"Primary Sj\u00f6gren's syndrome","volume":"378","author":"Mariette","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2022.105406_bib0370","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1093\/rheumatology\/kev200","article-title":"Characterization of systemic disease in primary Sjogren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements","volume":"54","author":"Ramos-Casals","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2022.105406_bib0375","first-page":"175","article-title":"Sj\u00f6gren's syndrome towards precision medicine: the challenge of harmonisation and integration of cohorts","volume":"37","author":"Goules","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2022.105406_bib0380","doi-asserted-by":"crossref","first-page":"191","DOI":"10.7150\/ijms.17718","article-title":"Reviewing primary Sj\u00f6gren's syndrome: beyond the dryness\u00a0\u2013\u00a0from pathophysiology to diagnosis and treatment","volume":"14","author":"Both","year":"2017","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.jbspin.2022.105406_bib0385","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1136\/ard.2009.110619","article-title":"EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome","volume":"69","author":"Seror","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105406_bib0390","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1136\/ard.2010.143743","article-title":"EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome","volume":"70","author":"Seror","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105406_bib0395","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2019-216114","article-title":"EULAR recommendations for the management of Sj\u00f6gren's syndrome with topical and systemic therapies","volume":"79","author":"Ramos-Casals","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105406_bib0400","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/annrheumdis-2016-210571","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism classification criteria for primary Sj\u00f6gren's syndrome: A consensus and data-driven methodology involving three international patient cohorts","volume":"76","author":"Shiboski","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105406_bib0405","first-page":"Cd009729","article-title":"Over the counter (OTC) artificial tear drops for dry eye syndrome","volume":"2","author":"Pucker","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jbspin.2022.105406_bib0410","first-page":"Cd009603","article-title":"Interventions for the management of dry mouth: non-pharmacological interventions","volume":"2013","author":"Furness","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jbspin.2022.105406_bib0415","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/bjd.16442","article-title":"Pilocarpine and artificial saliva for the treatment of xerostomia and xerophthalmia in Sj\u00f6gren syndrome: a double-blind randomized controlled trial","volume":"179","author":"Cifuentes","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jbspin.2022.105406_bib0420","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/art.510","article-title":"A double-blind, randomized, placebo-controlled study of cevimeline in Sj\u00f6gren's syndrome patients with xerostomia and keratoconjunctivitis sicca","volume":"46","author":"Petrone","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2022.105406_bib0425","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0161-6420(99)00176-1","article-title":"Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group","volume":"107","author":"Sall","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jbspin.2022.105406_bib0430","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.clae.2015.04.004","article-title":"Treatment of Sj\u00f6gren's syndrome dry eye using 0.03% tacrolimus eye drop: prospective double-blind randomized study","volume":"38","author":"Moscovici","year":"2015","journal-title":"Cont Lens Anterior Eye"},{"key":"10.1016\/j.jbspin.2022.105406_bib0435","doi-asserted-by":"crossref","first-page":"e553","DOI":"10.1016\/S2665-9913(21)00122-3","article-title":"Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS): development and validation of a novel outcome measure","volume":"3","author":"Arends","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jbspin.2022.105406_bib0440","article-title":"Development and preliminary validation of the Sj\u00f6gren's Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sj\u00f6gren's syndrome","author":"Seror","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105406_bib0445","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/nrrheum.2016.100","article-title":"Treatment of primary Sj\u00f6gren syndrome","volume":"12","author":"Saraux","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jbspin.2022.105406_bib0450","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.2014.7682","article-title":"Effects of hydroxychloroquine on symptomatic improvement in primary Sj\u00f6gren syndrome: the JOQUER randomized clinical trial","volume":"312","author":"Gottenberg","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jbspin.2022.105406_bib0455","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","article-title":"Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology","volume":"16","author":"Schrezenmeier","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jbspin.2022.105406_bib0460","article-title":"The efficiency of hydroxychloroquine for the treatment of primary Sj\u00f6gren's syndrome: a systematic review and meta-analysis","volume":"12","author":"Wang","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jbspin.2022.105406_bib0465","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/rheumatology\/kez242","article-title":"Hydroxychloroquine treatment downregulates systemic interferon activation in primary Sj\u00f6gren's syndrome in the JOQUER randomized trial","volume":"59","author":"Bodewes","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2022.105406_bib0470","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1042\/bj3360299","article-title":"Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide","volume":"336","author":"Bruneau","year":"1998","journal-title":"Biochem J"},{"key":"10.1016\/j.jbspin.2022.105406_bib0475","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1016\/S2665-9913(20)30057-6","article-title":"Leflunomide\u2013hydroxychloroquine combination therapy in patients with primary Sj\u00f6gren's syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial","volume":"2","author":"van der Heijden","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jbspin.2022.105406_bib0480","unstructured":"Assistance publique\u2013H\u00f4pitaux de P. New Clinical End-points in Patients With Primary Sj\u00f6gren's Syndrome. 2024."},{"key":"10.1016\/j.jbspin.2022.105406_bib0485","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1136\/annrheumdis-2015-208304","article-title":"Towards personalised treatment in primary Sj\u00f6gren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment","volume":"75","author":"Delli","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105406_bib0490","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/art.27314","article-title":"Effectiveness of rituximab treatment in primary Sj\u00f6gren's syndrome: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Meijer","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2022.105406_bib0495","doi-asserted-by":"crossref","first-page":"233","DOI":"10.7326\/M13-1085","article-title":"Treatment of primary Sj\u00f6gren syndrome with rituximab: a randomized trial","volume":"160","author":"Devauchelle-Pensec","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jbspin.2022.105406_bib0500","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/art.40093","article-title":"Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sj\u00f6gren's Syndrome","volume":"69","author":"Bowman","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2022.105406_bib0505","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1136\/ard.2007.083865","article-title":"Reduction of fatigue in Sj\u00f6gren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study","volume":"67","author":"Dass","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105406_bib0510","first-page":"217","article-title":"B cell depletion with rituximab in the treatment of primary Sj\u00f6gren's syndrome: what have we learnt?","volume":"37","author":"Grigoriadou","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2022.105406_bib0515","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","article-title":"B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial","volume":"81","author":"Furie","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105406_bib0520","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/annrheumdis-2018-214720","article-title":"Treatment of primary Sj\u00f6gren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity","volume":"78","author":"D\u00f6rner","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105406_bib0525","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(21)02251-0","article-title":"Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sj\u00f6gren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial","volume":"399","author":"Bowman","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2022.105406_bib0530","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jaut.2015.11.002","article-title":"Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sj\u00f6gren's syndrome","volume":"67","author":"Cornec","year":"2016","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jbspin.2022.105406_bib0535","first-page":"2249","article-title":"Efficacy and safety of belimumab given for 12 months in primary Sj\u00f6gren's syndrome: the BELISS open-label phase II study","volume":"54","author":"De Vita","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2022.105406_bib0540","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1136\/annrheumdis-2021-eular.2170","article-title":"OP0135 Safety and Efficacy of subcutaneous belimumab and intravenous rituximab combination in patients with primary sj\u00f6gren's syndrome: a phase 2, randomised, placebo-controlled 68-week study","volume":"80","author":"Mariette","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105406_bib0545","first-page":"73","article-title":"Sequential administration of belimumab and rituximab in primary Sj\u00f6gren's syndrome reduces minor salivary gland\u2013resident b cells and delays b-cell repopulation in circulation [abstract]","volume":"73","author":"Van Maurik","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2022.105406_bib0550","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/247426","article-title":"Effect of TACI signaling on humoral immunity and autoimmune diseases","volume":"2015","author":"Zhang","year":"2015","journal-title":"J Immunol Res"},{"key":"10.1016\/j.jbspin.2022.105406_bib0555","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.4049\/jimmunol.2000170","article-title":"Serine phosphorylation of the STAT1 transactivation domain promotes autoreactive B cell and systemic autoimmunity development","volume":"204","author":"Chodisetti","year":"2020","journal-title":"J Immunol"},{"key":"10.1016\/j.jbspin.2022.105406_bib0560","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.0105-2896.2005.00229.x","article-title":"Hyper immunoglobulin M syndrome due to CD40 deficiency: clinical, molecular, and immunological features","volume":"203","author":"Lougaris","year":"2005","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jbspin.2022.105406_bib0565","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.4049\/jimmunol.1100198","article-title":"Anti-CD180 (RP105) activates B cells to rapidly produce polyclonal Ig via a T cell and MyD88-independent pathway","volume":"187","author":"Chaplin","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.jbspin.2022.105406_bib0570","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/ard.2010.144782","article-title":"Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sj\u00f6gren's syndrome","volume":"70","author":"Theander","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105406_bib0575","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/sji.12121","article-title":"Upregulation of membrane-bound CD40L on CD4+ T cells in women with primary Sj\u00f6gren's syndrome","volume":"79","author":"Belkhir","year":"2014","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.jbspin.2022.105406_bib0580","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1016\/S2665-9913(19)30135-3","article-title":"Assessment of the anti-CD40 antibody iscalimab in patients with primary Sj\u00f6gren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study","volume":"2","author":"Fisher","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jbspin.2022.105406_bib0585","article-title":"A Phase 2a study of MEDI5872 (AMG557), a fully human anti-icos ligand monoclonal antibody in patients with primary Sj\u00f6gren's syndrome [abstract]","volume":"71","author":"Mariette","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2022.105406_bib0590","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/art.40513","article-title":"Clinical efficacy and safety of baminercept, a lymphotoxin \u03b2 receptor fusion protein, in primary Sj\u00f6gren's syndrome: results from a phase II randomized, double-blind, placebo-controlled trial","volume":"70","author":"St Clair","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2022.105406_bib0595","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nrd1989","article-title":"Abatacept","volume":"5","author":"Moreland","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jbspin.2022.105406_bib0600","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1002\/acr.22052","article-title":"Evaluation of histologic, serologic, and clinical changes in response to abatacept treatment of primary Sj\u00f6gren's syndrome: a pilot study","volume":"65","author":"Adler","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jbspin.2022.105406_bib0605","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1136\/annrheumdis-2013-204653","article-title":"Abatacept treatment reduces disease activity in early primary Sj\u00f6gren's syndrome (open-label proof of concept ASAP study)","volume":"73","author":"Meiners","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105406_bib0610","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1016\/S2665-9913(19)30160-2","article-title":"Abatacept treatment for patients with early active primary Sj\u00f6gren's syndrome: a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study)","volume":"2","author":"van Nimwegen","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jbspin.2022.105406_bib0615","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/annrheumdis-2020-218599","article-title":"Efficacy and safety of abatacept in active primary Sj\u00f6gren's syndrome: results of a phase III, randomised, placebo-controlled trial","volume":"80","author":"Baer","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105406_bib0620","doi-asserted-by":"crossref","first-page":"151955","DOI":"10.1016\/j.semarthrit.2022.151955","article-title":"Long-term abatacept treatment for 48 weeks in patients with primary Sj\u00f6gren's syndrome: the open-label extension phase of the ASAP-III trial","volume":"53","author":"de Wolff","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2022.105406_bib0625","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1136\/annrheumdis-2019-216588","article-title":"Salivary gland epithelial cells from patients with Sj\u00f6gren's syndrome induce B-lymphocyte survival and activation","volume":"79","author":"Rivi\u00e8re","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105406_bib0630","author":"Sciences","year":"2017","journal-title":"Study to assess safety and efficacy of filgotinib, lanraplenib and tirabrutinib in adults with active Sjogren's syndrome."},{"key":"10.1016\/j.jbspin.2022.105406_bib0635","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1124\/jpet.116.237347","article-title":"Seletalisib: characterization of a novel, potent, and selective inhibitor of PI3K\u03b4","volume":"361","author":"Allen","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jbspin.2022.105406_bib0640","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/rheumatology\/keaa410","article-title":"A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sj\u00f6gren's syndrome","volume":"60","author":"Juarez","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2022.105406_bib0645","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1136\/annrheumdis-2018-eular.3111","article-title":"OP0250 A randomised, double-blind study to assess the safety, tolerability and preliminary efficacy of leniolisib (CDZ173) in patients with primary sj\u00d6gren's syndrome","volume":"77","author":"D\u00f6rner","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105406_bib0650","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.csbj.2022.01.002","article-title":"Addressing the clinical unmet needs in primary Sj\u00f6gren's Syndrome through the sharing, harmonization and federated analysis of 21 European cohorts","volume":"20","author":"Pezoulas","year":"2022","journal-title":"Comput Struct Biotechnol J"},{"key":"10.1016\/j.jbspin.2022.105406_bib0655","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3389\/fonc.2019.00018","article-title":"Salt-inducible kinase 2: an oncogenic signal transmitter and potential target for cancer therapy","volume":"9","author":"Chen","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.jbspin.2022.105406_bib0660","doi-asserted-by":"crossref","first-page":"e000292","DOI":"10.1136\/rmdopen-2016-000292","article-title":"SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary Sj\u00f6gren's syndrome","volume":"2","author":"Rose","year":"2016","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2022.105406_bib0665","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1136\/annrheumdis-2016-210927","article-title":"High maternal expression of SIGLEC1 on monocytes as a surrogate marker of a type I interferon signature is a risk factor for the development of autoimmune congenital heart block","volume":"76","author":"Lisney","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105406_bib0670","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.3389\/fimmu.2020.01424","article-title":"Structural Understanding of Interleukin 6 family cytokine signaling and targeted therapies: focus on Interleukin 11","volume":"11","author":"Metcalfe","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jbspin.2022.105406_bib0675","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1016\/S0161-6420(98)91236-2","article-title":"Elevated tear interleukin-6 levels in patients with Sj\u00f6gren syndrome","volume":"105","author":"Tishler","year":"1998","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jbspin.2022.105406_bib0680","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/annrheumdis-2020-218467","article-title":"Interleukin 6 receptor inhibition in primary Sj\u00f6gren syndrome: a multicentre double-blind randomised placebo-controlled trial","volume":"80","author":"Felten","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105406_bib0685","doi-asserted-by":"crossref","first-page":"e30123","DOI":"10.1371\/journal.pone.0030123","article-title":"Interleukin-1 inhibition and fatigue in primary Sj\u00f6gren's syndrome--a double blind, randomised clinical trial","volume":"7","author":"Norheim","year":"2012","journal-title":"PLOS ONE"},{"key":"10.1016\/j.jbspin.2022.105406_bib0690","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/art.20146","article-title":"Inefficacy of infliximab in primary Sj\u00f6gren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sj\u00f6gren's Syndrome (TRIPSS)","volume":"50","author":"Mariette","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2022.105406_bib0695","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1002\/art.20299","article-title":"Etanercept in Sj\u00f6gren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial","volume":"50","author":"Sankar","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2022.105406_bib0700","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1073\/pnas.0408506102","article-title":"Cross-regulation of TNF and IFN-alpha in autoimmune diseases","volume":"102","author":"Palucka","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jbspin.2022.105406_bib0705","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/art.41489","article-title":"Improvement of severe fatigue following nuclease therapy in patients with primary Sj\u00f6gren's syndrome: a randomized clinical trial","volume":"73","author":"Posada","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2022.105406_bib0710","series-title":"A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis","author":"Momenta Pharmaceuticals","year":"2019"},{"key":"10.1016\/j.jbspin.2022.105406_bib0715","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1586\/1744666X.2015.1027151","article-title":"Iguratimod for the treatment of rheumatoid arthritis in Japan","volume":"11","author":"Tanaka","year":"2015","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jbspin.2022.105406_bib0720","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/03009742.2020.1809701","article-title":"Efficacy and safety of iguratimod on patients with primary Sj\u00f6gren's syndrome: a randomized, placebo-controlled clinical trial","volume":"50","author":"Shao","year":"2021","journal-title":"Scand J Rheumatol"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X22000653?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X22000653?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T16:28:19Z","timestamp":1761150499000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X22000653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":72,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S1297319X22000653"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2022.105406","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current and future treatment in primary Sj\u00f6gren's syndrome\u00a0\u2013\u00a0A still challenging development","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2022.105406","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105406"}}